Your Search Results

TMVR today: devices, challenges, and clinical learnings

12 Sep 2025 – From PCR Rio Valves 2025

Explore the evolving landscape of transcatheter mitral valve replacement (TMVR) with a focus on innovative devices, procedural challenges, and clinical learnings. Through a series of case reports, including novel atrial fixation prostheses, devices addressing left ventricular outflow tract obstruction, and complex MitraClip interventions, this session highlights...

Seal the deal: echocardioraphy-guided LAA closure for stroke defense

12 Sep 2025 – From PCR Rio Valves 2025

This session focuses on echocardiography-guided left atrial appendage (LAA) closure as a critical strategy for stroke prevention. Attendees will explore optimal cardiac imaging techniques tailored to evolving clinical needs and seasonal considerations. The session also includes comprehensive instruction on post-procedural echocardiographic assessment and post-processing workflows in...

Early outcomes and predictors of success in LATAM TAVI experiences

12 Sep 2025 – From PCR Rio Valves 2025

Explore early outcomes and predictors of success from Latin America's evolving experience with Transcatheter Aortic Valve Implantation (TAVI). This session covers innovative approaches such as transfemoral access intravascular lithotripsy compared to angioplasty, conduction disturbances with self-expandable TAVI devices, and insights from regional centers treating severe aortic...

Mitral valve - The role of the echocardiography imager pre and post intervention

11 Sep 2025 – From PCR Rio Valves 2025

This session emphasizes the critical role of echocardiography imaging pre- and post-mitral valve interventions. It includes case-based post-processing with comprehensive transthoracic and transesophageal echocardiography essential for decision-making in mitral TEER, identification and grading of recurrent mitral regurgitation, and evaluations related to mitral annular calcification and valve-in-calcification...

Addressing challenges in the right heart

11 Sep 2025 – From PCR Rio Valves 2025

This session addresses complex challenges associated with right heart conditions, featuring cases such as post-infarction interventricular septal defect with right heart failure, innovative orthotopic options for tricuspid regurgitation, and advanced edge-to-edge repair using the TRICLIP device. Gain insight into therapeutic strategies for managing severe tricuspid insufficiency...

Management of aortic stenosis: what really matters before and after the procedure

11 Sep 2025 – From PCR Rio Valves 2025

Aortic stenosis management is a lifetime strategy, not a one-time procedure. This session covers key decision-making factors, compares surgical and transcatheter options, and provides guidance on post-procedural care. Learn to individualise treatment based on age, anatomy, and risk, and plan interventions with the patient’s long-term trajectory...

Management of aortic stenosis: what really matters before and after the procedure

Tricuspid transcatheter therapies: the game changer

29 Sep 2025 – From PCR Gulf Valves 2025

Explore the evolving landscape of tricuspid transcatheter therapies in this comprehensive session reviewing tricuspid regurgitation etiology, anatomy, and current treatment options. Learn about various transcatheter tricuspid valve intervention devices, their strengths and limitations, and the critical diagnostic and intraprocedural imaging requirements to optimize patient selection and...

Tricuspid transcatheter therapies: the game changer

Mitral valve-in-valves: echocardiography and CT scan

29 Sep 2025 – From PCR Gulf Valves 2025

This session provides in-depth knowledge on imaging planning for mitral valve-in-valve procedures, focusing on echocardiography and CT scan assessment. Learn the critical role of intraprocedural imaging guidance to ensure procedural success and patient safety during mitral valve-in-valve interventions.

BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

07 Nov 2022

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...